RDY and DRRD:IN Related Headlines
Go Back- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Lowered to INR1,365 at ICICI Securities
- Kotak Reiterates Reduce (3) Rating on Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (RDY)
- Goldman Sachs Downgrades Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) to Sell
- Dr. Reddy's Laboratories Ltd. (DRRD:IN) (RDY) PT Lowered to INR1,259 at Morgan Stanley
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Raised to INR1,200 at JPMorgan
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Lowered to INR1,040 at Jefferies
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Lowered to INR1,480 at BofA Securities
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Lowered to INR1,285 at Morgan Stanley
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Raised to INR1,600 at Nomura/Instinet
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Raised to INR1,070 at Citi
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Raised to INR1,225 at Goldman Sachs
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Lowered to INR1,205 at Kotak
- Macquarie Reiterates Neutral Rating on Dr. Reddy's Laboratories (DRRD:IN) (RDY)
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Lowered to INR1,100 at Jefferies
- PhillipCapital Reiterates Buy (1) Rating on Dr. Reddy's Laboratories (DRRD:IN) (RDY)
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Lowered to INR1,170 at JPMorgan
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Lowered to INR1,580 at Nomura/Instinet
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Lowered to INR1,165 at Kotak
- Goldman Sachs Reiterates Neutral Rating on Dr. Reddy's Laboratories Ltd. (DRRD:IN) (RDY)
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Raised to INR1,190 at JPMorgan
- Dr. Reddy's Laboratories Ltd. (DRRD:IN) (RDY) PT Lowered to INR1,650 at Nomura/Instinet
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Raised to INR1,250 at ICICI Securities
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Lowered to INR1,230 at Axis Capital Limited
- Kotak Reiterates Reduce (3) Rating on Dr. Reddy's Laboratories Ltd. (DRRD:IN) (RDY)
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Raised to INR1,450 at HSBC
- Kotak Reiterates Reduce (3) Rating on Dr. Reddy's Laboratories Ltd. (DRRD:IN) (RDY)
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Raised to INR1,150 at JPMorgan
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Raised to INR1,660 at Nomura/Instinet
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Raised to INR1,090 at JPMorgan
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Raised to INR1,200 at ICICI Securities
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Raised to INR1,260 at Axis Capital Limited
- Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (RDY) PT Raised to INR1,100 at Jefferies
- Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (RDY) PT Raised to INR1,200 at Goldman Sachs
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Lowered to INR1,400 at HSBC
- Dr. Reddy's Laboratories Ltd. (DRRD:IN) (RDY) PT Lowered to INR1,175 at Goldman Sachs
- Morgan Stanley Starts Dr. Reddy's Laboratories Ltd. (DRRD:IN) (RDY) at Equalweight
- Macquarie Downgrades Dr. Reddy's Laboratories (DRRD:IN) (RDY) to Neutral
- Dr. Reddy's Laboratories (DRRD:IN) (RDY) PT Lowered to INR990 at Citi

